Adam FeuersteinVerified account

@adamfeuerstein

Senior Writer at . I am the Night King of biotech. Data Are. Dogs rule. Said one analyst: The likes of Adam Feuerstein attack viciously.

Boston, MA
statnews.com
Joined January 2010
3,453 Photos and videos Photos and videos

Tweets

You blocked @adamfeuerstein

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @adamfeuerstein

  1. 10 hours ago

    I can't row at 1:52 for five minutes. This insane person did it for six hours. Speechless.

    5 replies 22 likes
    Undo
  2. Retweeted
    13 hours ago

    -30% in AH --> FDA may want a new randomized trial for AndexXa before approval

    5 replies 18 retweets 18 likes
    Undo
  3. 13 hours ago

    I’m not a flu vaccine guy, but I keep reading and re-reading the PR and can’t find the line where it says NanoFlu seroconversion rate was favorable vs. Fluzone control.

    7 replies 5 retweets 16 likes
    Undo
  4. 14 hours ago

    When Maxim downgrades you to sell…

    7 replies 1 retweet 33 likes
    Undo
  5. 15 hours ago

    has cured cancer. Congrats, everyone.

    10 replies 4 retweets 30 likes
    Undo
  6. Retweeted
    17 hours ago

    Drug makers are seeking more orphan designations than ever before..

    1 reply 14 retweets 3 likes
    Undo
  7. 20 hours ago

    -16%

    Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint uh oh, .
    3 replies 2 retweets 11 likes
    Undo
  8. Retweeted
    20 hours ago

    Join us in congratulating STAT's , winner of the Beat Reporting Award for Excellence in Health Care Journalism from . Her stories challenge beliefs, spur conversation, and promote change. Way to go, Helen!

    5 replies 17 retweets 89 likes
    Show this thread
    Show this thread
    Undo
  9. 20 hours ago

    If you watched our genome editing webinar, you know CRISPR mouse data published and PR’d y’day doesn’t yet ease concerns raised by ongoing non-human primate studies.

    3 replies 2 retweets 6 likes
    Undo
  10. 21 hours ago

    Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint uh oh, .

    1 reply 5 retweets 7 likes
    Undo
  11. 21 hours ago

    Happy Rare Disease Day 2018, when we honor biopharma innovation in securing new orphan disease approvals for already-marketed drugs, thereby extending patent life and further gouging the healthcare system. 👏👏👏

    4 replies 8 retweets 59 likes
    Undo
  12. Feb 27

    Updated: stumbles again, as FDA declines to review multiple sclerosis drug critical to company future

    2 replies 4 retweets 9 likes
    Undo
  13. Feb 27

    Genentech received an RTF for Kadcyla. It shouldn’t happen to experienced drug makers, but it does. Not a excuse.

    5 replies 4 retweets 27 likes
    Undo
  14. Feb 27

    Yeezus.

    on cue-
    Show this thread
    1 like
    Undo
  15. Feb 27

    stumbles again, as FDA declines to review multiple sclerosis drug critical to company future

    6 replies 14 retweets 12 likes
    Undo
  16. Feb 27

    Jackie Fouse left and went to shit.

    11 replies 7 retweets 45 likes
    Undo
  17. Feb 27

    Refuse to file!

    Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis. NDA insufficient to permit a complete review
    3 replies 3 retweets 6 likes
    Undo
  18. Retweeted
    Feb 27

    A clarifying demonstratiom of how elitism and genetic technology may converge. Barbara Streisand cloned her dog.

    15 replies 73 retweets 88 likes
    Undo
  19. Feb 27

    At our STAT retreat today, the business team included — WSJ columnist — as one of our notable subscribers. Congrats, Charley!

    9 likes
    Undo
  20. Feb 27

    New healthcare digital media business plan: Charge biotech startups to write/publish check-cashing stories, instead of just giving them free publicity. Add premium surcharge if startup is preclinical or launched by .

    4 replies 3 retweets 15 likes
    Undo

@adamfeuerstein hasn't Tweeted yet.

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·